BVBenigno Valderrábano-Salas

Benigno Valderrábano-Salas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benigno Valderrábano-Salas has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Echocardiographic Alterations in Subjects with Sarcopenia and Right Heart Failure

    by Arturo Orea-Tejeda, Luis Aldo Delgado-Pérez, Benigno Valderrábano-Salas, Dulce González-Islas, Álvaro Montañez-Orozco, José Carlos Ruan-Díaz, María José Hernández-Hernández, Edgar Lozano-Hernández, Carlos Patricio Chávez-Guzmán, Karla García-Díaz

    Background: Chronic heart failure (HF) is a significant public health issue. The principal risk factors for left ventricular diastolic dysfunction (LVDD) include older age, female sex, obesity, hypertension, smoking, and diabetes, among others, all of which can reduce physical activity. Additionally, peripheral factors such as skeletal muscle mass (SMM) abnormalities decrease maximal oxygen consumption. In elderly HF patients, the prevalence of sarcopenia is higher than in those without HF; however, the relationship between sarcopenia and HF remains insufficiently explained, particularly in right HF (RHF). Our objective was to describe the echocardiographic alterations between sarcopenic and non-sarcopenic subjects with RHF. Methods: A cross-sectional study was conducted. Outpatients aged 18 years or older with a confirmed diagnosis of RHF were included. Sarcopenia was defined according to EWGSOP2. Results: A total of 183 patients were included; 24.5% had sarcopenia. The mean age was 64.34 ± 13.97 years. Echocardiographic characteristics revealed evidence of LVDD in sarcopenic subjects, as indicated by lower E wave velocity, E/A ratio, and e’ lateral and medial values, as well as lower right ventricular (RV) wall thickness compared with non-sarcopenic subjects. The multivariate model showed that sarcopenia subjects had lower RV wall thickness (B: −1.36 mm, 95% CI: −2.30 to −0.42), e’ medial (B: −1 cm/s, 95% CI: −1.99 to −0.02), and e’ lateral (B: −1.78 cm/s, 95% CI: −2.97 to −0.60). Conclusions: The prevalence of sarcopenia in RHF patients was 24.6%, which was associated with LVDD and lower RV wall thickness, suggesting a loss of cardiac muscle mass.

  • Open Access

    Dynapenia and Sarcopenia in Post-COVID-19 Syndrome Hospitalized Patients Are Associated with Severe Reduction in Pulmonary Function

    by Arturo Orea-Tejeda, Robinson Robles-Hernández, Dulce González-Islas, Luz Jimenez-Gallardo, Laura Gochicoa-Rangel, Armando Castorena-Maldonado, Rafael Hernández-Zenteno, Alvaro Montañez-Orozco, Benigno Valderrábano-Salas

    Background: After hospital discharge, post-COVID-19 syndrome has been observed to be associated with impaired diffusing capacity, respiratory muscle strength, and lung imaging abnormalities, in addition to loss of muscle mass/strength, sarcopenia, and obesity impact exercise tolerance, pulmonary functions, and overall prognosis. However, the relationship between lung function and the coexistence of obesity with low muscle strength and sarcopenia in post-COVID-19 patients remains poorly investigated. Therefore, our aim was to evaluate the association between lung function and the coexistence of obesity with dynapenia and sarcopenia in post-COVID-19 syndrome patients. Methods: This cross-sectional study included subjects who were hospitalized due to moderate to severe COVID-19, as confirmed by PCR testing. Subjects who could not be contacted, declined to participate, or died before the follow-up visit were excluded. Results: A total of 711 subjects were evaluated; the mean age was 53.64 ± 13.57 years, 12.4% had normal weight, 12.6% were dynapenic without obesity, 8.3% had sarcopenia, 41.6% had obesity, 21.2% had dynapenic obesity, and 3.8% had sarcopenic obesity. In terms of pulmonary function, the dynapenic subjects showed decreases of −3.45% in FEV1, −12.61 cmH2O in MIP, and -12.85 cmH2O in MEP. On the other hand, the sarcopenic subjects showed decreases of −6.14 cmH2O in MIP and −11.64 cmH2O in MEP. The dynapenic obesity group displayed a reduction of −12.13% in PEF. Conclusions: In post-COVID-19 syndrome, dynapenia and sarcopenia—both with and without obesity—have been associated with lower lung function.